Farra Chantal, Nassar Anwar H, Usta Ihab M, Salameh Pascale, Souaid Mirna, Awwad Johnny
Genetics Laboratories, Chronic Care Center, Hazmieh, Lebanon.
Prenat Diagn. 2008 Sep;28(9):828-32. doi: 10.1002/pd.2067.
The aim of the study was to assess the rate of acceptance of preimplantation genetic diagnosis (PGD) as an alternative to prenatal diagnosis in Lebanese women with previously affected children with homozygous beta-thalassemia.
Women with a previously affected child attending a non governmentally funded thalassemia care center between 1 June 2005 and 31 May 2007 were offered a genetic counseling session. This was followed by administering a questionnaire through direct interview.
All 97 women approached accepted to participate in the study (100% response rate). Sixty eight per cent of women considered PGD a better alternative to prenatal diagnosis. The most important perceived advantage of PGD was the avoidance of termination of an affected pregnancy.
PGD is an acceptable alternative to conventional prenatal diagnosis in women at risk of conceiving a child affected with beta-thalassemia. This is particularly true in countries of the Middle-East where therapeutic abortions for fetal indications are prohibited by the law and religion.
本研究旨在评估在黎巴嫩有先前患纯合子β地中海贫血患儿的妇女中,胚胎植入前遗传学诊断(PGD)作为产前诊断替代方法的接受率。
2005年6月1日至2007年5月31日期间,在一家非政府资助的地中海贫血护理中心就诊的有先前患患儿的妇女接受了遗传咨询。随后通过直接访谈进行问卷调查。
所有97名被邀请的妇女均同意参与研究(回复率100%)。68%的妇女认为PGD是产前诊断的更好替代方法。PGD最主要的优势在于可避免终止受影响的妊娠。
对于有生育患β地中海贫血患儿风险的妇女,PGD是传统产前诊断的可接受替代方法。在中东国家尤其如此,因为法律和宗教禁止因胎儿指征进行治疗性堕胎。